Nicotine Administration Exacerbates Lipid Profile Alterations in a Wistar Rat Model of Liver Fibrosis through Fatty Acid Synthesis Modulation
- 1 December 2025
- journal article
- research article
- Published by Pleiades Publishing Ltd in Biology Bulletin
- Vol. 52 (11) , 333
Abstract
Dyslipidemia is characterized by abnormal lipid levels in the bloodstream and can be influenced by liver diseases and smoking. Nicotine exposure and liver damage are linked to lipid metabolism impairments. This study investigated the effects of nicotine on dyslipidemia in a cholestasis rat model using bile duct ligation (BDL) to establish liver fibrosis. Wistar rats received intraperitoneal nicotine at doses of 10 mg/kg (high) and 1 mg/kg (low) for three weeks. Serum levels of triglycerides (TG), cholesterol (Chol), low-density lipoprotein (LDL), and high-density lipoprotein (HDL) were quantified via a standard colorimetric kit (Pars Azmoon). Liver fibrosis confirmed through histological investigation. Additionally, the mRNA and protein expression of fatty acid synthase (FAS) were assessed using quantitative RT-PCR and immunofluorescence. Results showed that nicotine administration in healthy rats significantly increased TG, Chol, and LDL levels while decreasing HDL. In BDL rats, nicotine further reduced HDL and increased TG levels without affecting Chol and LDL. Histological analysis confirmed hepatic fibrosis, and both nicotine exposure and liver fibrosis elevated FAS expression in liver tissues. These findings indicate that BDL-induced liver fibrosis causes dyslipidemia in rats, and nicotine exposure exacerbates serum lipid profile alterations, potentially through increased FAS expression. Therefore, it is recommended that individuals with liver disease avoid nicotine to manage dyslipidemia.Keywords
All Related Versions
This publication has 49 references indexed in Scilit:
- Sesamol protects against liver fibrosis induced in rats by modulating lysophosphatidic acid receptor expression and TGF-β/Smad3 signaling pathwayNaunyn-Schmiedeberg's Archives of Pharmacology, 2022
- Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver DiseaseCurrent Atherosclerosis Reports, 2022
- Treatment of Dyslipidemia in Common Liver DiseasesClinical Gastroenterology and Hepatology, 2018
- Agmatine protects rat liver from nicotine-induced hepatic damage via antioxidative, antiapoptotic, and antifibrotic pathwaysNaunyn-Schmiedeberg's Archives of Pharmacology, 2016
- Does hepatic vagus nerve modulate the progression of biliary fibrosis in rats?Autonomic Neuroscience, 2014
- Effect of endotoxin on heart rate dynamics in rats with cirrhosisAutonomic Neuroscience, 2013
- Fatty acid synthase and liver triglyceride metabolism: Housekeeper or messenger?Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2012
- Nicotine induces fibrogenic changes in human liver via nicotinic acetylcholine receptors expressed on hepatic stellate cellsBiochemical and Biophysical Research Communications, 2012
- Nitration of cardiac proteins is associated with abnormal cardiac chronotropic responses in rats with biliary cirrhosis†Hepatology, 2006
- Incidence of Coronary Heart Disease and Lipoprotein Cholesterol LevelsJAMA, 1986